Gilead Sciences (NASDAQ:GILD) CEO Daniel Patrick O’day Sells 10,000 Shares

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction on Monday, December 29th. The shares were sold at an average price of $124.83, for a total value of $1,248,300.00. Following the completion of the sale, the chief executive officer directly owned 566,698 shares of the company’s stock, valued at approximately $70,740,911.34. This trade represents a 1.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Daniel Patrick O’day also recently made the following trade(s):

• On Friday, November 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $126.54, for a total transaction of $1,265,400.00.
• On Tuesday, October 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00.

Gilead Sciences Price Performance

GILD stock traded down $1.73 during trading on Tuesday, reaching $123.18. 3,245,585 shares of the company were exchanged, compared to its average volume of 7,846,793. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The stock’s 50 day moving average price is $122.99 and its 200 day moving average price is $116.80. Gilead Sciences, Inc. has a 52-week low of $88.57 and a 52-week high of $128.70. The company has a market cap of $152.83 billion, a P/E ratio of 19.10, a PEG ratio of 0.69 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period last year, the firm earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.6%. Gilead Sciences’s dividend payout ratio is 48.99%.

Hedge Funds Weigh In On Gilead Sciences

A number of large investors have recently bought and sold shares of GILD. Triumph Capital Management raised its position in shares of Gilead Sciences by 16.5% in the 3rd quarter. Triumph Capital Management now owns 3,314 shares of the biopharmaceutical company’s stock worth $368,000 after buying an additional 470 shares during the period. AIA Group Ltd increased its stake in Gilead Sciences by 68.3% during the third quarter. AIA Group Ltd now owns 46,372 shares of the biopharmaceutical company’s stock worth $5,147,000 after acquiring an additional 18,826 shares during the last quarter. Mirabella Financial Services LLP raised its holdings in shares of Gilead Sciences by 32.7% in the 3rd quarter. Mirabella Financial Services LLP now owns 5,807 shares of the biopharmaceutical company’s stock worth $643,000 after purchasing an additional 1,430 shares during the period. Saranac Partners Ltd purchased a new position in shares of Gilead Sciences in the 3rd quarter worth about $118,000. Finally, Severin Investments LLC acquired a new position in shares of Gilead Sciences in the 3rd quarter valued at about $463,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of several recent research reports. Truist Financial began coverage on shares of Gilead Sciences in a research report on Monday, November 24th. They issued a “buy” rating and a $140.00 price objective on the stock. BMO Capital Markets set a $135.00 price target on shares of Gilead Sciences in a report on Tuesday, November 25th. Citigroup increased their price target on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Wednesday, October 8th. Sanford C. Bernstein set a $135.00 price objective on shares of Gilead Sciences and gave the stock an “outperform” rating in a research note on Monday. Finally, Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average price target of $131.68.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.